Osimertinib Mesylate
Brand name: Tagrisso
Rank #43 of 500 drugs by total cost
$436.5M
Total Cost
25,273
Total Claims
$436.5M
Total Cost
970
Prescribers
$17K
Cost per Claim
972
Beneficiaries
25,504
30-Day Fills
$450K
Avg Cost/Provider
26
Avg Claims/Provider
About Osimertinib Mesylate
Osimertinib Mesylate (sold as Tagrisso) was prescribed 25,273 times by 970 Medicare Part D providers in 2023, costing the program $436.5M. At $17K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 40 | Evolocumab (Repatha Sureclick) | $460.5M | 528,560 |
| 41 | Acalabrutinib Maleate (Calquence) | $457.0M | 31,890 |
| 42 | Atorvastatin Calcium (Atorvastatin Calcium) | $444.6M | 30,263,929 |
| 43 | Osimertinib Mesylate (Tagrisso) | $436.5M | 25,273 |
| 44 | Levothyroxine Sodium (Levothyroxine Sodium) | $435.3M | 20,209,418 |
| 45 | Deutetrabenazine (Austedo) | $404.1M | 60,532 |
| 46 | Linagliptin (Tradjenta) | $403.8M | 519,439 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology